Case Study

Phase 3 CAR T vs SOC in Relapse Refractory Multiple Myeloma (RRMM)

Assay Validation, Expertise And Continued Partnership With A Major Pharma

Scope

Patients Enrolled: 524

Sites: 95

Countries: 17

Regions: EU, US, Asia

Study duration: 32 months

Cerba Research validated a CAR T explor-atory panel and a PK panel (primary end-point)

Key Achievements

↑ Assay Validation fine-tuned with patient samples & spiked samples

↑ Strong established relationship with major pharma sponsor

↑ Involved in CAR T program early on

↑ ~7700 samples managed to date

Timeline

Jun '20	Aug '22	Sep '22
FPFV	LPLV	DBL

Challenges

Cerba Research involved in ~10 specialty tests

Such as immunophenotyping for a CAR T exploratory panel & FCM

Tracking PK as a primary endpoint

Solutions

Subcontracted some specialty tests

In house FCM design & validation

Cerba Research Data In-house (MSN F82); SOC=Standard Of Care; RRMM=Relapsed or Refractory Multiple Myeloma; FCM=Flow CytoMetry; FPFV=First-Patient First-Visit; LPLV=Last-Patient Last-Visit; DBL=DataBase Lock CAR T= Chimeric Antigen Receptor T cells